Gene therapy in rare disease

Gene therapy is one of the reasons rare disease can feel different today than it did a generation ago.

For some conditions, treatments are beginning to target the underlying genetic cause rather than only managing symptoms. For many other conditions, gene therapy is still experimental, unavailable, unsuitable, or not yet proven.

Both things can be true at once.

Gene therapy can be a source of real hope. It can also come with confusing headlines, strict eligibility criteria, high costs, limited access, and a lot of uncertainty.

Quick answer: gene therapy is a treatment approach that changes, replaces, adds to or affects genetic material in order to treat or prevent disease. In rare disease, it matters because many rare diseases have a genetic cause. But gene therapy is not available for most rare diseases, and a trial or news story does not mean a treatment is suitable, approved or accessible. [6] [7]

What is gene therapy?

Gene therapy is a medical approach that aims to treat or prevent disease by addressing a genetic problem.

Different gene therapies work in different ways. Some aim to add a working copy of a gene. Some aim to change how a gene behaves. Some use modified cells. Some use viral vectors, which are altered viruses used as delivery vehicles.

The science can be complex, but the basic idea is this:

Instead of only treating downstream symptoms, some gene therapies try to act closer to the genetic cause of the condition.

That does not make gene therapy simple. It also does not make it automatically curative. [6] [7]

Is gene therapy the same as genetic testing?

No.

Genetic testing is used to look for changes in genes that may help diagnose a condition, explain symptoms, guide care, inform family risk or support clinical trial decisions.

Gene therapy is a treatment approach.

A genetic diagnosis may sometimes be relevant to whether a person is eligible for a therapy or trial, but having a genetic diagnosis does not mean there is an available gene therapy.

Why does gene therapy matter in rare disease?

Many rare diseases are genetic. This makes rare disease an important area for genetic and advanced therapies. [1]

Gene therapy can matter because it may create a treatment route for conditions that previously had few or no disease-modifying options.

But it is important to be precise.

For families, the useful question is not only:

“Is there gene therapy?”

It is:

“Is there an approved, safe, suitable and accessible treatment or trial for this exact condition, gene, variant, age, stage and clinical situation?”

That is a much narrower question.

What is an advanced therapy?

In Europe, you may also see the term “advanced therapy medicinal product”, or ATMP.

ATMPs are medicines based on genes, cells or tissue engineering. Gene therapy medicines are one type of ATMP. [8]

This matters because advanced therapies often have specific regulatory, manufacturing, safety and access requirements. They are not ordinary medicines that can be prescribed casually.

Does a clinical trial mean a treatment works?

No.

A clinical trial is a research study designed to answer a specific question. That question may relate to safety, dose, side effects, effectiveness, eligibility, long term follow-up or another research objective.

A trial listing does not mean a treatment is proven. It does not mean it is approved. It does not mean every person with the condition can join.

It means the treatment or intervention is being studied.

Families should discuss any clinical trial with their healthcare team, especially because rare disease trials can have strict criteria. [9]

Why eligibility can be so specific

In rare disease, eligibility may depend on details such as:

• exact diagnosis

• gene involved

• variant type

• age

• weight

• disease stage

• previous treatments

• organ function

• mobility or respiratory status

• antibody status

• country or treatment centre

• trial location

• ability to travel

• long-term follow-up requirements

This can feel frustrating. A family may see a treatment headline and then discover their child or relative does not match the criteria.

That does not mean the headline was false. It means treatment access often depends on very specific details.

Why “available somewhere” is not the same as “available to us”

A therapy may be:

• approved in one country but not another

• available privately but not publicly funded

• available only through a trial

• available only before a certain age or disease stage

• available only at specialist centres

• available only with long-term monitoring

• not appropriate because of the person’s clinical situation

This is one of the hardest parts for families. The internet can show that something exists, but not whether it is realistic, safe, funded or relevant.

Example: Zolgensma for spinal muscular atrophy

One well-known example of gene therapy in rare disease is Zolgensma, also known as onasemnogene abeparvovec.

Zolgensma is used for spinal muscular atrophy, or SMA. SMA is a rare genetic condition that affects motor neurons, the nerve cells involved in movement. Many types of SMA are caused by changes in the SMN1 gene. [10]

Zolgensma is designed to deliver a functional copy of the SMN1 gene. In simple terms, it helps provide the body with a working copy of the gene needed to produce survival motor neuron protein, which is important for nerve function. [11]

This is why Zolgensma is often described as a gene replacement therapy.

But the access details matter.

In Europe, EMA describes Zolgensma as a gene therapy medicine for treating SMA, intended for patients with inherited SMN1 mutations who have SMA type 1 or up to 3 copies of SMN2. EMA also notes that it is given once as an infusion into a vein, under the supervision of a doctor experienced in managing SMA. [11]

In the UK, NICE has specific guidance on onasemnogene abeparvovec for treating SMA in babies, with separate guidance for presymptomatic SMA. [12] [13]

This example shows the wider point: even when a therapy exists, families still need to understand the exact condition, gene, age, stage, eligibility route, country-specific access pathway and clinical advice.

A therapy headline is not the same as a treatment plan.

What families can ask when they see treatment news

When you see a gene therapy headline, it may help to write down a few questions before your next appointment.

Is this relevant to the exact condition?

Ask:

• Is this for the same condition?

• Is it for the same gene?

• Is it for the same variant type?

• Is it for the same age group or disease stage?

What stage is it at?

Ask:

• Is this preclinical research, a clinical trial or an approved therapy?

• If it is a trial, what phase is it?

• Is it recruiting?

• Where is it taking place?

• Are results published or only announced in a press release?

What are the risks and monitoring needs?

Ask:

• What is known about short term risks?

• What is known about long term follow-up?

• What monitoring would be needed?

• What is still unknown?

What does access actually require?

Ask:

• Is it available in our country?

• Is it publicly funded, privately funded, trial-based or compassionate access?

• Would referral to a specialist centre be needed?

• Who can advise us properly?

Why careful language matters

Rare disease families do not need false hope. They also do not need hope taken away unnecessarily.

Good therapy information should be:

• clear about what is known

• honest about what is unknown

• specific about who it may apply to

• careful about early research

• clear about whether something is approved, trial-stage or theoretical

• practical about access

• respectful of families’ emotional reality

Words like “breakthrough”, “cure” and “life-changing” should be used carefully. They may be accurate in some contexts, but they can also flatten a much more complex reality.

What to keep in your care memory

If you are following treatment or trial news, it can help to keep:

• the exact condition name

• gene and variant details, if known

• key clinical details that may affect eligibility

• current specialist centre

• current treatments or therapies

• questions asked and answers received

• trial links or registry entries you want to discuss

• notes from conversations with clinicians

• published papers or charity updates

• dates of important treatment decisions

This does not replace medical advice. It simply makes the next conversation easier.

What to remember

Gene therapy is a real and important area of rare disease medicine.

It is not available for most rare diseases. It is not automatically suitable. It is not the same as a treatment recommendation. A trial listing does not mean a treatment has been proven or approved.

The most useful approach is to move from headline to specifics:

What condition? What gene? What evidence? What stage? What eligibility? What location? What risks? What does our clinical team think?

That is where hope becomes something families can investigate carefully.

How Rarevia can help

Rarevia is built to help rare disease families organise the information around diagnosis, daily changes, appointments, treatment questions and possible routes to investigate.